



## Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62<sup>nd</sup> Annual ESPE Meeting 2024

Oct 30, 2024

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- [Lumos Pharma](#) (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company's Phase 2 OraGrowth210 and OraGrowth212 clinical trials have been accepted for oral presentation at the [62<sup>nd</sup> Annual European Society for Paediatric Endocrinology Meeting](#), or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.

Two abstracts on data from the OraGrowth Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17<sup>th</sup>, by [Elżbieta Petriczko, MD, PhD](#), Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18<sup>th</sup>, by [Peter E. Clayton, MD](#), University of Manchester, Manchester, UK, respectively.

### LUM-201 Oral Abstract Presentations:

#### Sunday, November 17<sup>th</sup> – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time

- FC7.6 Abstract entitled, *Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowth210 and OraGrowth212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment* (Elżbieta Petriczko, MD, PhD, et al)

#### Monday, November 18<sup>th</sup> – Session: Free Communications 15: Late Breaking – 9:40AM Local Time

- FC15.2 Abstract entitled, *Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD)* (Peter E. Clayton, MD, et al)

### About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~\$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

### Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.